- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Current Hepatology Reports
December 2018, Volume 17, Issue 4, pp 502–510 | Cite as
Long-term Outcomes in Patients with HBV Treated with Antiviral Agents
Authors
Authors and affiliations
Mauro ViganòAlessandro LoglioPietro LamperticoEmail author
Mauro Viganò
1
Alessandro Loglio
2
Pietro Lampertico
2Email author
1.Hepatology Division, Ospedale San GiuseppeUniversità degli Studi di MilanoMilanItaly
2.CRC “A. M. and A. Migliavacca” Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoUniversità degli Studi di MilanoMilanItaly
Hepatitis B (J Lim, Section Editor)
First Online: 05 November 2018
1 Shares 29 Downloads
Part of the following topical collections:
Topical Collection on Hepatitis B
Abstract
ᅟ
Chronic hepatitis B (CHB) infection is one of the main causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. Long-term treatment with the most potent nucleos(t)ide analogues (NUCs), i.e., entecavir (ETV), tenofovir disoproxil fumarate (TDF), and the recently approved tenofovir alafenamide (TAF) are able to achieve and maintain virological suppression, and therefore are the first-line recommended therapies for all CHB patients.
Purpose of Review
To assess the long-term outcome in CHB patients treated with NUCs.
Recent Findings
These NUCs are highly effective in suppressing viral replication, thus preventing decompensation and reducing the risk of HCC. The 8-year survival of NUCs-treated patients is excellent, similar to that of the general population.
Summary
Long-term virological suppression with NUCs can significantly improve the long-term outcomes of CHB patients.
Keywords
Antiviral treatment ETV Hepatitis B HCC TAF TDF
Abbreviations
HBV
Hepatitis B virus
NUCs
Nucleot(s)ide analogs
CHB
Chronic hepatitis B
ETV
Entecavir
TDF
Tenofovir disoproxil fumarate
TAF
Tenofovir alafenamide
LMV
Lamivudine
ADV
Adefovir dipivoxil
HBsAg
Hepatitis B surface antigen
ALT
Alanine aminotransferase
HCC
Hepatocellular carcinoma
Peg-IFN
Pegylated Interferon
MELD
Model for end-stage liver disease
BMI
Body mass index
EV
Esophageal varices
HBeAg
Hepatitis B e antigen
This article is part of the Topical Collection on Hepatitis B |
|